Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Claps

Showing results (91-100 of 94) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 94 results.
International Urology and Nephrology|January 3, 2026
Defining the optimal duration of maintenance mitomycin C in intermediate-risk Ta NMIBC: a multicenter retrospective landmark analysisRoberto Contieri, Letizia Maria Ippolita Jannello, Mihai Dorin Vartolomei, et al.
European Urology Oncology|January 20, 2023
Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non-muscle-invasive SpectrumIrene J Beijert, Anouk E Hentschel, Johannes Bründl, et al.
International Urology and Nephrology|November 19, 2023
Second TURB, restaging TURB or repeat TURB in primary T1 non-muscle invasive bladder cancer: impact on prognosis?Irene J Beijert, Anouk E Hentschel, Johannes Bründl, et al.
European Urology Oncology|May 21, 2025
Towards Defining Follow-up Strategies for Patients with Primary Intermediate-risk Non-muscle-invasive Bladder CancerRoberto Contieri, Alberto Martini, Irene J Beijert, et al.
Pageof 10

Showing results (91-100 of 94) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 94 results.
International Urology and Nephrology|January 3, 2026
Defining the optimal duration of maintenance mitomycin C in intermediate-risk Ta NMIBC: a multicenter retrospective landmark analysisRoberto Contieri, Letizia Maria Ippolita Jannello, Mihai Dorin Vartolomei, et al.
European Urology Oncology|January 20, 2023
Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non-muscle-invasive SpectrumIrene J Beijert, Anouk E Hentschel, Johannes Bründl, et al.
International Urology and Nephrology|November 19, 2023
Second TURB, restaging TURB or repeat TURB in primary T1 non-muscle invasive bladder cancer: impact on prognosis?Irene J Beijert, Anouk E Hentschel, Johannes Bründl, et al.
European Urology Oncology|May 21, 2025
Towards Defining Follow-up Strategies for Patients with Primary Intermediate-risk Non-muscle-invasive Bladder CancerRoberto Contieri, Alberto Martini, Irene J Beijert, et al.
Pageof 10